InvestorsHub Logo
Followers 466
Posts 26949
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 133

Tuesday, 03/27/2012 4:05:45 PM

Tuesday, March 27, 2012 4:05:45 PM

Post# of 181
8:06AM Targacept announces 'Top-line' results from two exploratory Phase 2 studies of TC-6987; co will not pursue further development of TC-6987 as a treatment for diabetes (TRGT) 5.41 : Co announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met protocol-defined success criteria on both co-primary outcome measures, change from baseline in forced expiratory volume for adjunct TC-6987 compared to adjunct placebo measured at two time points on day 28. TC-6987 was generally well tolerated in both studies. There were no clinically meaningful changes in cardiovascular parameters in either study, an important finding that differentiates TC-6987 from many other alpha7 modulators. Co-Primary Endpoints in Asthma Study Achieved. In the type 2 diabetes study, the primary outcome measure, change in fasting plasma glucose, was not met, and Targacept will not pursue further development of TC-6987 as a treatment for diabetes. TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor discovered by Targacept scientists using Pentad, the company's proprietary drug discovery platform.


surf's up......crikey